Seeking Alpha

Regen Bio provides an update on IND

  • Bio-Matrix Scientific Group (BMSN +70.8%) subsidiary Regen BioPharma provides an update on its follow up on the FDA's issues regarding its HemaXellerate IND. On March 6, 2014 the company submitted a protocol modification, additional details on manufacturing, new data on the therapeutic effects of HemaXellerate I in animal models of diseases similar to aplastic anemia in humans and additional safety data to the FDA.
  • The agency accepted the clinical protocol and product manufacturing information but requested clarification on the animal safety studies.
  • On May 9, the company updated the IND and submitted it to the FDA for review.
Comments (2)
  • Mickey45
    , contributor
    Comments (9) | Send Message
     
    Stay tunes for the next update in the distant further of somethings like the drug Hema fails miserably,Hell most drugs pass no a days doesn`t matter about side effects look what we have out there now side effects like sudden death might occur u might go blind etc etc
    27 May, 04:03 AM Reply Like
  • Mickey45
    , contributor
    Comments (9) | Send Message
     
    Where does all the money go to when all the money for Cancer research go to?How many people think they are looking for a cure for Cancer?
    27 May, 04:14 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|